Nucleic acids for inhibiting expression of LPA in a cell

US11319537B2 · kind B2 · utility

Assignee

• Sapience Therapeutics, Inc. · DE

Inventors

• Sibylle Dames · Berlin, DE
• Steffen Schubert · Berlin, DE
• Stephan Tenbaum · Biberach an der Riß, DE
• Christian Frauendorf · Berlin, DE
• Lucas Bethge · Potsdam, DE
• Judith Hauptmann · Berlin, DE
• Adrien Weingärtner · Berlin, DE
• David Anthony Rider · Berlin, DE

Key dates

• Filing date: Nov 13, 2018
• Grant date: May 3, 2022
• Expiry date: Nov 13, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/351
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.